These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37256584)

  • 21. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Defining the Roles and Research Priorities for Psychedelic-Assisted Therapies in Patients with Serious Illness: Expert Clinicians' and Investigators' Perspectives.
    Beaussant Y; Sanders J; Sager Z; Tulsky JA; Braun IM; Blinderman CD; Bossis AP; Byock I
    J Palliat Med; 2020 Oct; 23(10):1323-1334. PubMed ID: 32233936
    [No Abstract]   [Full Text] [Related]  

  • 24. Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.
    Greenway KT; Garel N; Jerome L; Feduccia AA
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):655-670. PubMed ID: 32478631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelic drugs for psychiatric disorders.
    da Costa SC; Oesterle T; Rummans TA; Richelson E; Gold M
    J Neurol Sci; 2022 Sep; 440():120332. PubMed ID: 35841696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic-assisted psychotherapy for the treatment of major depression: a synthesis of phenomenological explanations.
    Miceli McMillan R; Jordens C
    Med Health Care Philos; 2022 Jun; 25(2):225-237. PubMed ID: 35064398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice.
    Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M
    J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.
    Schimmers N; Breeksema JJ; Smith-Apeldoorn SY; Veraart J; van den Brink W; Schoevers RA
    Psychopharmacology (Berl); 2022 Jan; 239(1):15-33. PubMed ID: 34812901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of potential psychedelic treatments for PTSD.
    Henner RL; Keshavan MS; Hill KP
    J Neurol Sci; 2022 Aug; 439():120302. PubMed ID: 35700643
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The need for establishing best practices and gold standards in psychedelic medicine.
    Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM
    J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes and Beliefs about the Therapeutic Use of Psychedelic Drugs among Psychologists in the United States.
    Davis AK; Agin-Liebes G; España M; Pilecki B; Luoma J
    J Psychoactive Drugs; 2022; 54(4):309-318. PubMed ID: 34468293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prescribing meaning: hedonistic perspectives on the therapeutic use of psychedelic-assisted meaning enhancement.
    Miceli McMillan R
    J Med Ethics; 2021 Oct; 47(10):701-705. PubMed ID: 33148774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Setting on Psychedelic Experiences, Therapies, and Outcomes: A Rapid Scoping Review of the Literature.
    Golden TL; Magsamen S; Sandu CC; Lin S; Roebuck GM; Shi KM; Barrett FS
    Curr Top Behav Neurosci; 2022; 56():35-70. PubMed ID: 35138585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychedelics and hypnosis: Commonalities and therapeutic implications.
    Lemercier CE; Terhune DB
    J Psychopharmacol; 2018 Jul; 32(7):732-740. PubMed ID: 29938563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelics and Psychotherapy: Cognitive-Behavioral Approaches as Default.
    Yaden DB; Earp D; Graziosi M; Friedman-Wheeler D; Luoma JB; Johnson MW
    Front Psychol; 2022; 13():873279. PubMed ID: 35677124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelic-Assisted Therapy for Substance Use Disorders and Potential Mechanisms of Action.
    Rieser NM; Herdener M; Preller KH
    Curr Top Behav Neurosci; 2022; 56():187-211. PubMed ID: 34910289
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Psychedelic Psychiatry: Preparing for Novel Treatments Involving Altered States of Consciousness.
    Holoyda B
    Psychiatr Serv; 2020 Dec; 71(12):1297-1299. PubMed ID: 33050796
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Self-blinding citizen science to explore psychedelic microdosing.
    Szigeti B; Kartner L; Blemings A; Rosas F; Feilding A; Nutt DJ; Carhart-Harris RL; Erritzoe D
    Elife; 2021 Mar; 10():. PubMed ID: 33648632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.